%A ZHANG Bei-Bei, SONG Zheng-Bo, ZHANG Yi-Ping-* %T Advances in the the epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment %0 Journal Article %D 2013 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2013.07.016 %P 526-529 %V 40 %N 7 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9129.shtml} %8 2013-07-08 %X Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.